TG Therapeutics to Present at Jefferies Global Healthcare Conference
ByAinvest
Monday, Jun 2, 2025 8:05 am ET1min read
RMSG--
The presentation comes on the heels of positive data from the ULTIMATE I & II Phase 3 trials and the ENHANCE study, which were presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. These trials highlighted BRIUMVI®'s safety and efficacy in treating RMS, with no association between decreased serum immunoglobulin levels and serious infections observed in long-term treatment [1]. Additionally, real-world data from the ENAMOR survey indicated favorable infusion tolerability for BRIUMVI®, and updates from the ENHANCE study confirmed the safety and tolerability of 30-minute infusions [2].
However, the data also raised concerns about infusion reactions and infections. Infusion reactions were reported in 48% of BRIUMVI-treated patients, with serious reactions in 0.6% of cases. Serious infections were slightly higher in BRIUMVI-treated patients compared to those treated with teriflunomide [1]. The drug is contraindicated in patients with active Hepatitis B Virus infection and those with a history of life-threatening infusion reactions [2].
The upcoming conference provides an opportunity for investors to gain insights into TG Therapeutics' strategic direction and the potential market impact of BRIUMVI®. Weiss's participation underscores the company's commitment to addressing unmet needs in RMS treatment and its ability to differentiate BRIUMVI® through unique glycoengineering technology [1].
References:
[1] https://www.gurufocus.com/news/2898276/tg-therapeutics-inc-tgtx-showcases-promising-briumvi-data-at-cmsc-2025-tgtx-stock-news
[2] https://www.globenewswire.com/news-release/2025/05/30/3090994/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-2025-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html
SRM--
TGTX--
TG Therapeutics announced that CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference. Weiss will deliver a fireside chat on June 4, 2025, at 12:50 PM ET. A live webcast of the event will be available on the company's website. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases.
TG Therapeutics Inc. (TGTX) has announced that CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference on June 4, 2025, at 12:50 PM ET. The event will feature a fireside chat with Weiss, who will discuss the company's latest advancements and the potential of BRIUMVI® (ublituximab-xiiy), a novel treatment for relapsing forms of multiple sclerosis (RMS).The presentation comes on the heels of positive data from the ULTIMATE I & II Phase 3 trials and the ENHANCE study, which were presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. These trials highlighted BRIUMVI®'s safety and efficacy in treating RMS, with no association between decreased serum immunoglobulin levels and serious infections observed in long-term treatment [1]. Additionally, real-world data from the ENAMOR survey indicated favorable infusion tolerability for BRIUMVI®, and updates from the ENHANCE study confirmed the safety and tolerability of 30-minute infusions [2].
However, the data also raised concerns about infusion reactions and infections. Infusion reactions were reported in 48% of BRIUMVI-treated patients, with serious reactions in 0.6% of cases. Serious infections were slightly higher in BRIUMVI-treated patients compared to those treated with teriflunomide [1]. The drug is contraindicated in patients with active Hepatitis B Virus infection and those with a history of life-threatening infusion reactions [2].
The upcoming conference provides an opportunity for investors to gain insights into TG Therapeutics' strategic direction and the potential market impact of BRIUMVI®. Weiss's participation underscores the company's commitment to addressing unmet needs in RMS treatment and its ability to differentiate BRIUMVI® through unique glycoengineering technology [1].
References:
[1] https://www.gurufocus.com/news/2898276/tg-therapeutics-inc-tgtx-showcases-promising-briumvi-data-at-cmsc-2025-tgtx-stock-news
[2] https://www.globenewswire.com/news-release/2025/05/30/3090994/8790/en/TG-Therapeutics-Announces-Data-Presentations-for-BRIUMVI-in-Multiple-Sclerosis-at-the-2025-Consortium-of-Multiple-Sclerosis-Centers-Annual-Meeting.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet